Article • Omics in cancer care

Personalizing laboratory medicine

To avoid adverse reactions, personalised laboratory medicine can help to predict a patient’s drug response. Investigations based on DNA and other omics technologies – e.g. genomics, transcriptomics, proteomics, metabolomics – along with microarray technologies, is making a particularly valuable contribution to cancer care, in which personalised approaches are becoming possible through molecular profiling.

Report: Mark Nicholls

portrait of Matthias Schwab
Prof Matthias Schwab

Matthias Schwab, Professor and Chair of Clinical Pharmacology at the University of Tübingen, who also heads the Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart, Germany, believes that personalised laboratory medicine will have an increasingly important role in patient care over the next decade. However, he emphasises that the technique must be used in line with guidelines and recommendations – and where there is a clear consequence to the action, such as in drug selection or adjustment of dose.

This is particularly important in drugs that have a narrow therapeutic window, where the dose used is close to that which may result in drug-related toxicity. ‘Personalised laboratory medicine in healthcare is currently mostly implemented for treatment of oncology patients to avoid adverse drug reactions,’ he explained, adding that, in some areas, such as colorectal cancer, the approach is clearly defined – and where drugs (e.g. 5-Fluorouracil) to be used in clinical practice should be laboratory tested with a personalised medicine approach, for example to prevent haematoxicity and/or gastrointestinal side effects. ‘Personalised laboratory medicine is a crucial step in ensuring the dose is correct, that the treatment is correct, and matches the patient’s DNA, genetic profile and condition,’ Schwab emphasised. ‘Guidelines for healthcare implementation, that are regularly updated and publicly available, are there for doctors to select the right drug and adjust dose, or in some cases choose another drug. Personalised laboratory medicine also has value in research, by using consented information from a patient’s DNA to answer specific research questions.’

Recommended article

Photo

Article • Screening, early detection, treatment optimisation

AI techniques advancing oncology care

Cancer care and the treatment clinicians can offer patients is being increasingly enhanced by Artificial Intelligence (AI). The technology has a role in diagnosis, with algorithms trained to design and deliver patient care, can match patients to clinical trials they may benefit from, and even help predict outcomes and those at greatest risk.

Trends and applications in personalised laboratory medicine involve the application of newer drugs in cancer therapy, such as epidermal growth factor receptor (EGFR) inhibitors in lung cancer and can support genetic testing in therapy selection. With around 15 different drug targets (e.g. genes) and genetic variation, the technology can help clinicians select the right drug and dose in a process mostly conducted together with a pathologist using lung tissue.

Schwab feels this is the most promising application, but he foresees a move towards pre-emptive testing, not only in cases of drug failure after conventional cancer therapy, but also at the onset of therapy, where genetic information will be available when prescribing. When discussing personalised laboratory medicine in genomics, he emphasises that it is important to clearly define the genome variation. Germline DNA from individuals will ease this pre-emptive approach while, in cancer patients, personalised laboratory medicine must focus on DNA from the tumour. For patients with a tumour, where Next Generation Sequencing is currently mainly conducted only in cancer relapses, he suggests that, within the next decade, this will be a routine pre-emptive pharmacogenetic test.

To Schwab, the benefits of personalised laboratory medicine are clear. ‘It’s about better treatment and selective drugs that will work if you carry a specific mutation, meaning patients will receive individualised treatment and not suffer toxicity.’ Such a medical approach promises more effective diagnostics with more effective and safer treatment, as well as faster recovery and restoration of health and improved cost effectiveness. ‘Personalised medicine in the genomics area is the future,’ he concluded, ‘but, in the next few years we will also talk about liquid biopsies because we can also use this information for epigenetic or metabolomic markers.’


Profile:

Matthias Schwab is Professor and Chair of Clinical Pharmacology and heads the Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart and the Department of Clinical Pharmacology, University Hospital, Tübingen, Germany. His major clinical and research activities are personalised medicine and pharmacogenomics with focus on cancer.

19.08.2021

Read all latest stories

Related articles

Photo

Article • Tissue-engineered glioblastoma model

3D brain tumour in a dish to personalize cancer treatment

It is the size of a common pencil eraser, but it could have a huge impact on the therapy of glioblastoma: Scientists in Virginia have developed a novel 3D tissue-engineered model of the brain tumour…

Photo

News • Bioprinting in cancer

3D printing patient-specific tumours

Bowel cancer patients could in future benefit from a new 3D bioprinting technology which would use their own cells to replicate the complex cellular environment of solid tumours in 3D models.

Photo

News • Children’s cancer

Rhabdomyosarcoma: Blood tests could offer smarter treatment

A simple 'liquid biopsy' blood test could help guide the treatment of children with the cancer rhabdomyosarcoma, a new study reports.

Related products

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
ASP Lab Automation – SortPro Sample sorter

Sample Processing

ASP Lab Automation – SortPro Sample sorter

ASP Lab Automation AG
Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Subscribe to Newsletter